Nasdaq:US$14.53 (-0.13) | HKEX:HK$22.70 (-0.24) | AIM:£2.22 (-0.02)
Search Result
Previous Article   |   Next Article
Scientific Publications | 3 Nov 2021

NANETS 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors